MedPath

Study to Compare the Safety of Immediate One-stage IBBR With Expander-Implant Two-stage IBBR Augmented With TiLoop® Bra(COSTA)

Not Applicable
Active, not recruiting
Conditions
Breast Cancer
Interventions
Procedure: Immediate IBBR+TiLoop®Bra
Procedure: Immediate-delayed IBBR+TiLoop®Bra
Registration Number
NCT03589924
Lead Sponsor
Jiong Wu
Brief Summary

This study is the first prospective randomized study assessing the safety and patient-reported outcomes of immediate one-stage IBBR compared with those of two-stage IBBR with TiLoop® Bra.

Detailed Description

Studies comparing two-stage implant-based breast reconstruction with immediate one-stage implant-based breast reconstruction have inconsistent results and investigators find that there is a lack of high quality evidence focusing on comparing one-stage and two-stage implant-based breast reconstruction with TiLoop®Bra.

This study is the first prospective randomized study assessing the safety and patient-reported outcomes of immediate one-stage IBBR compared with those of two-stage IBBR with TiLoop® Bra in breast cancer patients.

The hypothesis is that one step method is not inferior to two step method in implant based breast reconstruction following skin-sparing and/or Nipple-sparing mastectomy using TiLoop® Bra.

The current study is a randomized multicenter, open labeled, prospective, controlled study.

Participants were enrolled at six hospitals in different places of China. All participants will undergo Skin Sparing Mastectomy(SSM)/Nipple Sparing Mastectomy(NSM) with one-stage or two stage IBBR with TiLoop® Bra.

Based on earlier experience, investigators calculated that the surgical complication rate was approximately 30 percent in the one-stage group and 25 percent in the two-stage group. Consider a dropout rate of 5%, a total of 450 patients, with 225 in each group, are needed.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
Female
Target Recruitment
440
Inclusion Criteria
  • Patients with histological proven invasive breast cancer or ductal carcinoma in situ;
  • Clinical T1-T2 disease with no distant metastasis;
  • Patient with clinical N0 status;
  • Intent to receive NSM or SSM and implant based breast reconstruction;
  • Signed consent to participate.
Exclusion Criteria
  • Patient with severe breast ptosis;
  • Patient received ipsilateral breast reduction or enlargement;
  • Locally advanced stage patients who received neoadjuvant chemotherapy or hormone therapy;
  • Patients enrolled in other clinical trial which may as influence the outcome;
  • Patients received neo-adjuvant therapy and will receive radiotherapy.
  • History of breast cancer (ipsilateral, i.e. recurrence, or contralateral breast);
  • Patients of pregnancy or lactation.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
One step methodImmediate IBBR+TiLoop®BraImmediate implant reconstruction following mastectomy using TiLoop®Bra (one step method) n=225
Two step methodImmediate-delayed IBBR+TiLoop®BraImmediate-delayed implant reconstruction following mastectomy using TiLoop®Bra (two step method) n=225
Primary Outcome Measures
NameTimeMethod
Rate of perioperative complicationsStart of randomization until 3 months after surgery

The rate of perioperative complication between the two groups

Secondary Outcome Measures
NameTimeMethod
Quality of life:EORTC QLQ C30 /+ BR23 questionnaire18 months after surgery

EORTC QLQ C30 /+ BR23(EORTC breast cancer-specific quality of life) questionnaire to evaluate quality of life.

Participants report the extent to which they have experienced those symptoms or problems during the past week. Each of the symptoms or problems is indicated with four extents, including "not at all" for 1 score,"a little" for 2 score, "quit a bit" for 3 score and "very much" for 4 score. A higher score indicated a worse quality of life.

Aesthetic score of reconstructed breast18 months after surgery

Harris evaluation system to evaluate patients' breast aesthetic after surgery. Harris evaluation system is a 4-staged subjective evaluation method scored as "excellent," "good," "fair," "poor" .

Angiopathology-related assessment of Tiloop bra18 months after surgery

The angiopathology-related assessment in immediate-delayed reconstruction group

Patient satisfaction:Breast-Q questionnaire18 months after surgery

Breast-Q questionnaire to evaluate patients' satisfaction Using the reconstruction module of BREAST-Q to evaluate patient-reported outcome (PRO) of the surgery.For each subtheme, one or more BREAST-Q scales were developed to examine specific aspects of patient satisfaction.

Patient responses to each scale's items are transformed through the Q-Score scoring software to provide a total scale score that ranges from 0 to 100. For all BREAST-Q scales, a higher score means greater satisfaction.

Additional surgery18 months after surgery

The type of additional surgery following breast reconstruction

Trial Locations

Locations (11)

Sun Yat-sen Memorial Hospital,Sun Yat-sen University

🇨🇳

Guangzhou, Guangdong, China

Hebei Cancer Hospital

🇨🇳

Shijia Zhuang, Hebei, China

Guangdong Women and Children Hospital

🇨🇳

Guangzhou, Guangdong, China

Jiangsu Province Hospital

🇨🇳

Nanjing, Jiangsu, China

The first hospital of China medical university

🇨🇳

Shengyang, Liaoning, China

Liaoning Cancer Hospital & Insitute

🇨🇳

Shenyang, Liaoning, China

The Affiliated Hospital of Qingdao University

🇨🇳

Qingdao, Shandong, China

Cancer Hospital/ Institute, Fudan University

🇨🇳

Shanghai, Shanghai, China

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

🇨🇳

Hangzhou, Zhejiang, China

Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine

🇨🇳

Hangzhou, Zhejiang, China

The Second Affiliated Hospital of Zhejiang University

🇨🇳

Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath